Pharmacological profile of T-1032, a novel specific phosphodiesterase type 5 inhibitor, in isolated rat aorta and rabbit corpus cavernosum

European Journal of Pharmacology

Volumn 411, Issue 1-2, 2001, Pages 161-168

  Takagi, Michino ^a   Mochida, Hideki ^a   Noto, Tsunehisa ^a   Yano, Koji ^a   Inoue, Hirotaka ^a   Ikeo, Tomihiro ^a   Kikkawa, Kohei ^a  

^a MITSUBISHI TANABE PHARMA CORPORATION   (Japan)

Author keywords

Aorta; Corpus cavernosum; Cyclic nucleotide; Phosphodiesterase type 5 inhibitor; Rabbit; Rat; Relaxation

Indexed keywords

1H 1,2,4 OXADIAZOLO[4,3 A]QUINOXALIN 1 ONE; 2 (4 AMINOPHENYL) 1,2 DIHYDRO 1 OXO 7 (2 PYRIDINYLMETHOXY) 4 (3,4,5 TRIMETHOXYPHENYL) 3 ISOQUINOLINECARBOXYLIC ACID METHYL ESTER; ARGININE; CYCLIC AMP; CYCLIC GMP; ISOPRENALINE; METHYL 2 (4 AMINOPHENYL) 1,2 DIHYDRO 1 OXO 7 (2 PYRIDINYLMETHOXY) 4 (3,4,5 TRIMETHOXYPHENYL) 3 ISOQUINOLINE; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; NITROPRUSSIDE SODIUM; PHENYLEPHRINE; PHOSPHODIESTERASE INHIBITOR; SILDENAFIL; TETRODOTOXIN; UNCLASSIFIED DRUG;

ANIMAL TISSUE; AORTA CONSTRICTION; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORPUS CAVERNOSUM; DRUG EFFECT; DRUG POTENCY; DRUG SELECTIVITY; MALE; NONHUMAN; PRIORITY JOURNAL; RABBIT; RAT; SIGNAL TRANSDUCTION;

3',5'-CYCLIC-GMP PHOSPHODIESTERASE; ANIMALS; AORTA, THORACIC; ARGININE; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTRIC STIMULATION; ISOPROTERENOL; ISOQUINOLINES; MALE; MUSCLE RELAXATION; NG-NITROARGININE METHYL ESTER; NITROPRUSSIDE; OXADIAZOLES; PAPAVERINE; PENIS; PHENYLEPHRINE; PHOSPHODIESTERASE INHIBITORS; PHOSPHORIC DIESTER HYDROLASES; PIPERAZINES; PYRIDINES; QUINOXALINES; RABBITS; RATS; RATS, WISTAR; TETRODOTOXIN; VASOCONSTRICTOR AGENTS; VASODILATION; VASODILATOR AGENTS;

EID: 0035184939     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(00)00907-9     Document Type: Article

References (42)

1. Organic nitrate esters: Clinical use and mechanisms of actions
2. Physiology of penile erection
3. Influence of denervation on neurogenic inhibitory response of corpus cavernosum and nitric oxide synthase histochemistry
4. Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes
5. Cyclic nucleotide phosphodiesterases: Functional implications of multiple isoforms
6. Sildenafil, a novel effective oral therapy for male erectile dysfunction
7. Nitric oxide is a potent relaxant of human and rabbit corpus cavernosum
8. Cyclic GMP phosphodiesterase-5: Target of sildenafil
9. Identifying protein kinases in crude extracts that phosphorylate cyclic GMP-binding cyclic-GMP specific phosphodiesterase
10. Effect of papaverine on cyclic nucleotide levels in the isolated rat aorta
11. Prevention of cyclic GMP breakdown can enhance the effects of endogenous natriuretic peptides in heart failure
12. Endothelium-derived relaxing and contracting factors
13. Potent and selective inhibition of nitric oxide-sensitive guanylyl cyclase by 1H-[1,2,4]oxadiazolo[4,3-a] quinoxalin-1-one
14. Neurogenic nitric oxide mediates relaxation of canine corpus cavernosum
15. Nitric oxide-cyclic GMP signal transduction system
16. Characterization of inhibitory neurotransmission in the isolated corpus cavernosum from rabbit and man
17. Pharmacology of endothelium-derived nitric oxide and nitrovasodilators
18. T-1032, a new specific phosphodiesterase type V inhibitor, increases venous capacity in anesthetized rats
19. Characterization and phosphorylation of PDE10A2, a novel alternative splice variant of human phosphodiesterase that hydrolyzes cAMP and cGMP
20. Characterization and effects of methyl-2-(4-aminophenyl)-1,2-dihydro-1-oxo-7-(2-pyridinylmethoxy)-4-(3,4,5 -trimethoxyphenyl)-3-isoquinoline carboxylate sulfate (T-1032), a novel potent inhibitor of cGMP-binding cGMP-specific phosphodiesterase (PDE5)
21. Cyclic nucleotides and relaxation of vascular smooth muscle
22. Sildenafil: A review of its use in erectile dysfunction
23. A comparison of the effects of forskolin and nitroprusside on cyclic nucleotides and relaxation in the rat aorta
24. Distinct and specific functions of cGMP-dependent protein kinases
25. Cyclic nucleotide-mediated regulation of vascular smooth muscle cell cyclic nucleotide phosphodiesterase activity. Selective effect of cyclic AMP
26. Multiple roles of the messenger molecule cGMP in testicular function
27. Sildenafil, a novel inhibitor of phosphodiesterase type 5 in human corpus cavernosum smooth muscle cells
28. cGMP mediates the vascular and platelet actions of nitric oxide: Confirmation using an inhibitor of the soluble guanylyl cyclase
29. Cyclic nucleotide PDE-3. Quantitation of PDE-3A and -3B mRNAs in rat tissues by RNase protection assay
30. Nitric oxide and cyclic GMP formation following relaxant nerve stimulation in isolated human corpus cavernosum
31. Cyclic nucleotide phosphodiesterases and vascular smooth muscle
32. Effects of atrial natriuretic factor, sodium nitroprusside, and acetylcholine on cyclic GMP levels and relaxation in rat aorta
33. Characterization of three inhibitors of endothelial nitric oxide synthase in vitro and in vivo
34. Effects of a novel inhibitor of guanylyl cyclase on dilator responses of mouse cerebral arterioles
35. Regulation of cAMP and cGMP signaling: New phosphodiesterases and new functions
36. Cyclic nucleotide phosphodiesterase in human cavernous smooth muscle
37. 2 formation in aorta and vena cava
38. Effect of cGMP inhibitors on the actions of nitrodilators in rat aorta
39. Antiplatelet and antiproliferative effects of SCH 51866, a novel type 1 and type 5 phosphodiesterase inhibitor
40. Cyclic GMP synthesis and function
41. Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro
42. Cardiovascular effects of T-1032, a novel and selective phosphodiesterase type V inhibitor, in normal and pulmonary hypertensive dogs